NASDAQ:LGVN - Nasdaq - US54303L2034 - Common Stock - Currency: USD
Overall LGVN gets a fundamental rating of 3 out of 10. We evaluated LGVN against 559 industry peers in the Biotechnology industry. While LGVN seems to be doing ok healthwise, there are quite some concerns on its profitability. LGVN is valied quite expensively at the moment, while it does show a decent growth rate.
Industry Rank | Sector Rank | ||
---|---|---|---|
ROA | -122.67% | ||
ROE | -149.05% | ||
ROIC | N/A |
Industry Rank | Sector Rank | ||
---|---|---|---|
OM | N/A | ||
PM (TTM) | N/A | ||
GM | 82.29% |
Industry Rank | Sector Rank | ||
---|---|---|---|
Debt/Equity | 0 | ||
Debt/FCF | N/A | ||
Altman-Z | -6.56 |
Industry Rank | Sector Rank | ||
---|---|---|---|
Current Ratio | 5.61 | ||
Quick Ratio | 5.61 |
Industry Rank | Sector Rank | ||
---|---|---|---|
PE | N/A | ||
Fwd PE | N/A |
Industry Rank | Sector Rank | ||
---|---|---|---|
P/FCF | N/A | ||
EV/EBITDA | N/A |
Industry Rank | Sector Rank | ||
---|---|---|---|
Dividend Yield | N/A |
1.27
+0.04 (+3.25%)
Industry Rank | Sector Rank | ||
---|---|---|---|
Dividend Yield | N/A |
Industry Rank | Sector Rank | ||
---|---|---|---|
PE | N/A | ||
Fwd PE | N/A | ||
P/S | 8.57 | ||
P/FCF | N/A | ||
P/OCF | N/A | ||
P/B | 1.11 | ||
P/tB | 1.28 | ||
EV/EBITDA | N/A |
Industry Rank | Sector Rank | ||
---|---|---|---|
ROA | -122.67% | ||
ROE | -149.05% | ||
ROCE | N/A | ||
ROIC | N/A | ||
ROICexc | N/A | ||
ROICexgc | N/A | ||
OM | N/A | ||
PM (TTM) | N/A | ||
GM | 82.29% | ||
FCFM | N/A |
Industry Rank | Sector Rank | ||
---|---|---|---|
Debt/Equity | 0 | ||
Debt/FCF | N/A | ||
Debt/EBITDA | N/A | ||
Cap/Depr | 97.16% | ||
Cap/Sales | 49.21% | ||
Interest Coverage | N/A | ||
Cash Conversion | N/A | ||
Profit Quality | N/A | ||
Current Ratio | 5.61 | ||
Quick Ratio | 5.61 | ||
Altman-Z | -6.56 |